Radiation plus a tumor injection, with or without cetuximab
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding a special drug given directly into a head-and-neck tumor during radiation can improve outcomes. It also looks at whether cetuximab (an antibody medicine) should be added for people who cannot or should not have certain standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 60 or older
- Your cancer is squamous cell cancer in the mouth, throat (oropharynx/hypopharynx), or supraglottic voice box area
- Your cancer is staged as T3–4 with NX, or T2 with N2–3, and you are a candidate for definite radiation treatment
- Your tumor is suitable for an injection directly into the lesion (one main spot doctors can inject)
- You cannot receive the usual platinum chemotherapy with radiation (for reasons such as kidney function, certain nerve/hearing problems, heart condition, or specific age-related health scores)
- Your day-to-day function is good (ECOG 0–1) and you are expected to live at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
Hear when a new Carcinoma, Squamous Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.